Corbus Pharmaceuticals Holdings (CRBP) Total Debt (2013 - 2024)

Corbus Pharmaceuticals Holdings' Total Debt history runs 6 years deep, the most recent figure standing at $10.7 million for Q2 2024.

• On a quarterly basis, Total Debt fell 41.4% year-over-year to $10.7 million in Q2 2024; TTM through Jun 2024 was $10.7 million, a 41.4% decrease from a year earlier, with the FY2023 full-year figure at $31.8 million, up 69.41% from the prior year.
• Total Debt slipped to $10.7 million in Q2 2024 per CRBP's latest filing, from $12.8 million in the prior quarter.
• Across five years, Total Debt topped out at $31.8 million in Q4 2023 and bottomed at $10.7 million in Q2 2024.
• The 5-year median for Total Debt is $18.5 million (2021), against an average of $18.5 million.
• Across the five-year window, Total Debt surged 69.41% in 2023 and slumped 41.4% in 2024, its largest moves.
• Year by year, Total Debt stood at $18.0 million in 2020, then climbed by 3.89% to $18.7 million in 2021, then gained by 0.27% to $18.8 million in 2022, then jumped by 69.41% to $31.8 million in 2023, then plunged by 66.23% to $10.7 million in 2024.
• Per Business Quant, the three latest CRBP Total Debt figures stand at $10.7 million (Q2 2024), $12.8 million (Q1 2024), and $31.8 million (Q4 2023).